{"denoms":[{"counts":[{"groupId":"BG000","value":"243"},{"groupId":"BG001","value":"251"},{"groupId":"BG002","value":"494"}],"units":"Participants"}],"groups":[{"description":"Participants with Relapsed/Refractory Multiple Myeloma (RRMM) received intravenous (IV) infusion of 2.5 milligram (mg)/kilogram (kg) belantamab mafodotin on Day 1 of each 21-day Cycle until disease progression, intolerable toxicity, death, informed consent withdrawal, or study end, whichever comes first in combination with 1.3 mg/meter\\^2 (m\\^2) Bor administered subcutaneously (SC) once daily on Days 1, 4, 8 and 11 of each 21-day cycle along with 20 mg Dex via oral tablet or IV infusion once daily on Days 1, 2, 4, 5, 8, 9, 11, and 12 of each 21-day cycle for a total of 8 cycles.","id":"BG000","title":"Belantamab Mafodotin + Bortezomib (Bor) + Dexamethasone (Dex)"},{"description":"Participants with RRMM received 16 mg/kg Daratumumab IV infusion once weekly of each 21-day cycle in Cycle 1 to Cycle 3; once every 3 weeks on Day 1 of each 21-day cycle in Cycle 4 to Cycle 8; and once every 4 weeks on day 1 of each 28-day cycle from cycle 9 onwards until disease progression, intolerable toxicity, death, informed consent withdrawal, or study end, whichever comes first in combination with 1.3 mg/m\\^2 Bor administered SC once daily on Days 1, 4, 8 and 11 of each 21-day cycle along with 20 mg Dex oral tablet or IV infusion once daily on Days 1, 2, 4, 5, 8, 9, 11, and 12 of each 21-day cycle for a total of 8 cycles.","id":"BG001","title":"Daratumumab + Bor + Dex"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"9.47","value":"64.5"},{"groupId":"BG001","spread":"10.11","value":"63.6"},{"groupId":"BG002","spread":"9.80","value":"64.0"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"YEARS"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"115"},{"groupId":"BG001","value":"107"},{"groupId":"BG002","value":"222"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"128"},{"groupId":"BG001","value":"144"},{"groupId":"BG002","value":"272"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"30"},{"groupId":"BG001","value":"41"},{"groupId":"BG002","value":"71"}],"title":"Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"213"},{"groupId":"BG001","value":"208"},{"groupId":"BG002","value":"421"}],"title":"Not Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"2"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Ethnicity (NIH/OMB)","unitOfMeasure":"Participants"}]}